Square Pharmaceuticals began in 1958 with an initial investment of 17,000 taka. It has since become the top pharmaceutical company in Bangladesh, achieving numerous milestones such as becoming a public company in 1991. Orion Pharma also began as a small company and went public in 2013. Both companies focus on producing quality, innovative healthcare products while conducting ethical business practices and benefiting shareholders, employees, and society. They face opportunities such as export growth but also threats from increasing competition.

1. 1

2. Presentation on: Square Pharmaceuticals Ltd. and
Orion Pharma Ltd.
2
Group Name: “ Justice League”
Group members
SL NAME ID
01 Abu Naiem 16102192
02 Jarin Tasnim Pathan 16102217
03 Farzana Binte Murad Ieera 16102193
04 Iven Tamassum Ellin 16102216
05 Md. Imon Sheikh 16102035

3. 3
 1958: Started SQUARE Pharma as a partnership business with a total initial
investment of Rs 17,000.
 1962: Opened a branch in Hatkhola road, Dhaka.
 1964: Transformed into a private limited company.
 1974 & 1982:Started Technical Collaboration and became licensee
 1985 & 1987:
– Achieved first position in the Pharmaceutical Market of Bangladesh
– Became pioneer in exporting pharmaceutical products.
 1991: SQUARE Pharmaceuticals went public

4. 4

5. 5
 1998: Agrochemicals and Veterinary Products Division.
 2004: SQUARE Pharmaceuticals Ltd was enlisted as UNICEF’s global
supplier.
 2009: SQUARE Pharmaceuticals began manufacturing insulin, hormone
and steroid products maintaining quality standards of US FDA and UK
MHRA.

6. 6
We view business as a means to the material and social wellbeing of the
investors, employees and the society at large, leading to accretion of wealth
through financial and moral gains as a part of the process of the human
civilization.

7. 7
Our Mission is to produce and provide quality & innovative healthcare relief
for people, maintain stringently ethical standard in business operation also
ensuring benefit to the shareholders, stakeholders and the society at large.

8. 8
Our objectives are to conduct transparent business operation based on
market mechanism within the legal and social frame work with aims to
attain the mission reflected by our vision.

9. 9
 Square pharmaceutical Offer five categories of product. Like as:
 Products by Trade Name.
 Products by Therapeutic Class.
 Products by Generic Name.
 Products by Herbal & Nutraceuticals.
 Products by Agrovet & Pesticides.

10. 10

11. 11
The Four Generic strategies are as follows:
 Cost leadership
 Differentiation
 Market niche focus
 Information technology Strategies

12. Strength Weakness
12
 Highly experienced and skilled
employees.
 Reputed company.
 customer base
 Raw materials
 Create benchmark
 Strong Corporate Governance
 Customer Loyalty
 Absence of Advanced
Technology
 Less Organized
 Time Consuming Decision
Making Process
 Inefficient Debt-Asset
Management
 Inefficient Debt-Asset
Management

13. Opportunity Threats
13
 Govt. Support
 Exporting abroad, entering global
market
 Possible new product units
 Larger Market share
 Number of competitors
 Volatile exchange rate
 Innovative products by others
 Inadequate Power supply

14. 14
Before January 2011 Orion Pharmacy was called Orion laboratories. In
2013 Orion Pharma went public by floating its shares in the Dhaka Stock
Exchange. It had submitted its IPO prospectus in 2011 to regulators. From
2016 Orion started to offer 20 medical scholarship as part of its corporate
social responsibility. In February 2017 it borrowed 34 million dollar from
the German BHF-Bank to finance expansion.

15. 15
To be regarded as a world-class corporate house through products, services
and values.

16. 16
 Continuous development of people competency
 Recognizing individual contribution
 Introducing new and innovative products and technologies
 Assuring quality products from advanced manufacturing facilities
 Exceeding customer satisfaction and granting trust through quality
services

17. 17
 Tablet
 Capsule
 Powder or Suspension
 Oral Liquid
 Cream and Ointment
 Injection

18. 18
 Threats of entry posed by new or potential competitors
 Degree of rivalry among existing companies
 Bargaining power of buyers
 Bargaining power of suppliers
 Threat of Substitute Products

19. Strength Weakness
19
 Cost effective technology
 Strong and well-developed
manufacturing base
 Low- cost manpower
 High-quality formulations and
drugs
 Lack of strategic planning
 Low R&D investments
 Production of duplicate drugs

20. Opportunities Threats
20
 Incredible export potential
 Increasing health consciousness
 New innovative therapeutic
products
 Drug delivery system
management
 Competition from MNCs
 Poor marketing methods
 Tariff barriers

21. 21

22. 22
IT department charge of the following:
 Server and Storage
 Communication
 Accounting
 Data management
 Inventory management
 Asset management
 Sales and distribution management
 Supply chain management
 Distribution Management

23. 23

24. 24